Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315.HK)
HKD 11.8
(3.87%)
HKD 11.8
(3.87%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -76.64 Million | -303.26 Million | -365.77 Million | -225.31 Million |
| Net Income | -380.15 Million | -601.35 Million | -545.64 Million | -476.69 Million |
| Depreciation & Amortization | 182.44 Million | 174.09 Million | 128.09 Million | 43.36 Million |
| Deferred income taxes | - | - | 4.58 Million | 101.46 Million |
| Stock-based compensation | 30.97 Million | 15.31 Million | 27.75 Million | 132.45 Million |
| Change in working capital | -9.23 Million | 95.64 Million | -10.17 Million | -29.23 Million |
| Other non-cash items | 85.23 Million | 13.02 Million | 29.61 Million | 3.32 Million |
| Investing Cash Flow | -100.27 Million | -153.73 Million | -84.13 Million | -188.18 Million |
| Investments in PPE | -126.61 Million | -240.67 Million | -198.66 Million | -306.42 Million |
| Acquisitions | - | -6.85 Million | - | 10 Million |
| Investment purchases | - | -9.3 Million | -540 Million | -1.27 Billion |
| Sales/Maturities of investments | - | 101.46 Million | 649.78 Million | 1.39 Billion |
| Other Investing Activities | -100.27 Million | 1.63 Million | 4.75 Million | -9.95 Million |
| Financing Cash Flow | -37.81 Million | 587.2 Million | 219.44 Million | 868.44 Million |
| Debt repayment | -169.08 Million | -29.98 Million | -57.13 Million | -16.85 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -8.19 Million | -18.98 Million | - | - |
| Common Stock Issuance | - | 521.05 Million | 311.04 Million | 98.36 Million |
| Other Financing Activities | -141.7 Million | 115.11 Million | -34.46 Million | 786.93 Million |
| Accounts receivables | -39.01 Million | -4.59 Million | -35.86 Million | -32.38 Million |
| Accounts payables | - | 4.59 Million | 35.86 Million | 32.38 Million |
| Inventory | 3.45 Million | -10.84 Million | -34.43 Million | -7.77 Million |
| Other working capital | 4.09 Million | 106.49 Million | 24.25 Million | -21.45 Million |
| Cash at beginning of period | 610.88 Million | 466.44 Million | 697.29 Million | 246.38 Million |
| Cash at end of period | 399.6 Million | 610.88 Million | 466.44 Million | 697.29 Million |
| Capital Expenditure | -126.61 Million | -240.67 Million | -198.66 Million | -306.42 Million |
| Effect of forex changes on cash | 3.46 Million | 14.24 Million | -380 Thousand | -4.03 Million |
| Net cash flow / Change in cash | -211.27 Million | 144.43 Million | -230.84 Million | 450.91 Million |
| Free Cash Flow | -203.26 Million | -543.93 Million | -564.44 Million | -531.73 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -25.33 Million | -25.33 Million | -380.15 Million | -96.57 Million | -96.57 Million | -94.9 Million |
| Depreciation & Amortization | 42.73 Million | 42.73 Million | 182.44 Million | 49.19 Million | 49.19 Million | 42.03 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.54 Million | 2.54 Million | 30.97 Million | 9.28 Million | 9.28 Million | 6.19 Million |
| Change in working capital | - | - | -9.23 Million | -15.56 Million | -15.56 Million | - |
| Other non-cash items | -5.13 Million | -5.13 Million | 85.23 Million | 24.11 Million | 24.11 Million | 37.88 Million |
| Investing Cash Flow | -15.98 Million | -15.98 Million | -100.27 Million | -5.13 Million | -5.13 Million | -45 Million |
| Investments in PPE | -11.21 Million | -11.21 Million | -126.61 Million | -18.18 Million | -18.18 Million | -45.12 Million |
| Acquisitions | - | - | - | - | - | 262.38 Thousand |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -4.76 Million | -4.76 Million | -100.27 Million | 13.05 Million | 13.05 Million | 116 Thousand |
| Financing Cash Flow | -6.73 Million | -6.73 Million | -37.81 Million | -29.66 Million | -29.66 Million | 10.75 Million |
| Debt repayment | - | - | -169.08 Million | - | - | -44.86 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -190.5 Thousand | -190.5 Thousand | -8.19 Million | 472 Thousand | - | -4.33 Million |
| Common Stock Issuance | - | - | - | - | - | -2.9 Million |
| Other Financing Activities | -6.54 Million | -6.54 Million | -141.7 Million | -30.13 Million | -29.66 Million | 59.95 Million |
| Accounts receivables | - | - | -39.01 Million | -19.5 Million | -19.5 Million | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | 3.45 Million | 1.89 Million | 1.89 Million | - |
| Other working capital | - | - | 4.09 Million | 2.04 Million | 2.04 Million | - |
| Cash at beginning of period | - | - | 610.88 Million | - | - | 703.53 Million |
| Cash at end of period | -6.87 Million | -6.87 Million | 399.6 Million | -67.57 Million | -67.57 Million | 594.52 Million |
| Capital Expenditure | -11.21 Million | -11.21 Million | -126.61 Million | -18.18 Million | -18.18 Million | -45.12 Million |
| Effect of forex changes on cash | 1.03 Million | 1.03 Million | 3.46 Million | -3.23 Million | -3.23 Million | 4.97 Million |
| Net cash flow / Change in cash | -6.87 Million | -6.87 Million | -211.27 Million | -67.57 Million | -67.57 Million | -109 Million |
| Free Cash Flow | 3.58 Million | 3.58 Million | -203.26 Million | -47.72 Million | -47.72 Million | -53.9 Million |
HPAIW
3923
JVTSF
XIACF
1143
0390